日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

贝伐珠单抗一线治疗卵巢癌随机试验的最终总生存期

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.19.01009
Tewari, Krishnansu S; Burger, Robert A; Enserro, Danielle; Norquist, Barbara M; Swisher, Elizabeth M; Brady, Mark F; Bookman, Michael A; Fleming, Gini F; Huang, Helen; Homesley, Howard D; Fowler, Jeffrey M; Greer, Benjamin E; Boente, Matthew; Liang, Sharon X; Ye, Chenglin; Bais, Carlos; Randall, Leslie M; Chan, John K; Ferriss, J Stuart; Coleman, Robert L; Aghajanian, Carol; Herzog, Thomas J; DiSaia, Philip J; Copeland, Larry J; Mannel, Robert S; Birrer, Michael J; Monk, Bradley J
肿瘤
肿瘤免疫
卵巢癌
发表日期：2019
文献求助 收藏

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study

贝伐珠单抗一线治疗晚期卵巢癌的III期随机试验中胃肠道不良事件的风险因素：妇科肿瘤协作组研究

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.2013.53.6524
Burger, Robert A; Brady, Mark F; Bookman, Michael A; Monk, Bradley J; Walker, Joan L; Homesley, Howard D; Fowler, Jeffrey; Greer, Benjamin E; Boente, Matthew; Fleming, Gini F; Lim, Peter C; Rubin, Stephen C; Katsumata, Noriyuki; Liang, Sharon X
肿瘤
肿瘤免疫
卵巢癌
发表日期：2014
文献求助 收藏

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

贝伐单抗治疗复发性和持续性卵巢癌或腹膜癌的妇科肿瘤组 II 期试验中的预测性和预后性血管生成标志物

期刊:Gynecologic Oncology
影响因子:4.1
doi:10.1016/j.ygyno.2010.08.016
Han Ernest S, Burger Robert A, Darcy Kathleen M, Sill Michael W, Randall Leslie M, Chase Dana, Parmakhtiar Basmina, Monk Bradley J, Greer Benjamin E, Connelly Patrick, Degeest Koen, Fruehauf John P
肿瘤
卵巢癌
血管生成
发表日期：2010
文献求助 收藏